Dodge & Cox Neurocrine Biosciences Inc Transaction History
Dodge & Cox
- $160 Billion
- Q4 2024
A detailed history of Dodge & Cox transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Dodge & Cox holds 3,016,425 shares of NBIX stock, worth $341 Million. This represents 0.26% of its overall portfolio holdings.
Number of Shares
3,016,425
Previous 1,287,820
134.23%
Holding current value
$341 Million
Previous $148 Million
177.7%
% of portfolio
0.26%
Previous 0.09%
Shares
6 transactions
Others Institutions Holding NBIX
# of Institutions
655Shares Held
95.2MCall Options Held
282KPut Options Held
281K-
Black Rock Inc. New York, NY14.2MShares$1.61 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.1MShares$1.15 Billion0.02% of portfolio
-
State Street Corp Boston, MA4.89MShares$553 Million0.03% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il2.54MShares$287 Million0.06% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.49MShares$282 Million0.54% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $10.8B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...